### Company Presentation Sessions Schedule

#### MORNING: 10:30 a.m. – Noon

<table>
<thead>
<tr>
<th>TIME</th>
<th>GATSBY ROOM</th>
<th>LECTURE SUITE</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30 a.m. – 10:40 a.m.</td>
<td>3d Biotek, LLC</td>
<td>BrainTemp, Inc.</td>
</tr>
<tr>
<td>10:40 a.m. – 10:50 a.m.</td>
<td>Micro Interventional Devices, Inc.</td>
<td>iHealthScreen, Inc.</td>
</tr>
<tr>
<td>10:50 a.m. – 11:00 a.m.</td>
<td>Intrommune Therapeutics</td>
<td>dB Diagnostic Systems, Inc.</td>
</tr>
<tr>
<td>11:00 a.m. – 11:10 a.m.</td>
<td>Neuronasal, LLC</td>
<td>Elemental Machines</td>
</tr>
<tr>
<td>11:10 a.m. – 11:20 a.m.</td>
<td>Mito BioPharma</td>
<td>Shifa Biomedical Corporation</td>
</tr>
<tr>
<td>11:20 a.m. – 11:30 a.m.</td>
<td>Grace Therapeutics, Inc.</td>
<td>Goldilocks Therapeutics, Inc.</td>
</tr>
<tr>
<td>11:30 a.m. – 11:40 a.m.</td>
<td>Kaydence Pharma A.S.</td>
<td>Covalent Bioscience, Inc.</td>
</tr>
<tr>
<td>11:40 a.m. – 11:50 a.m.</td>
<td>ConSynance Therapeutics, Inc.</td>
<td>PolyAurum, LLC</td>
</tr>
</tbody>
</table>

#### AFTERNOON: 2:00 p.m. – 3:30 p.m.

<table>
<thead>
<tr>
<th>TIME</th>
<th>GATSBY ROOM</th>
<th>LECTURE SUITE</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:00 p.m. – 2:10 p.m.</td>
<td>ContraFect Corporation</td>
<td>Helsinn Therapeutics (U.S.), Inc.</td>
</tr>
<tr>
<td>2:10 p.m. – 2:20 p.m.</td>
<td>OncoSec Medical, Inc.</td>
<td>SHINKEI Therapeutics, LLC</td>
</tr>
<tr>
<td>2:20 p.m. – 2:30 p.m.</td>
<td>SCYNEXIS, Inc.</td>
<td>Sapience Therapeutics, Inc.</td>
</tr>
<tr>
<td>2:30 p.m. – 2:40 p.m.</td>
<td>Amicus Therapeutics, Inc.</td>
<td>ARKAY Therapeutics, LLC</td>
</tr>
<tr>
<td>2:40 p.m. – 2:50 p.m.</td>
<td>Tyme Technologies, Inc.</td>
<td>Chromocell Corporation</td>
</tr>
<tr>
<td>2:50 p.m. – 3:00 p.m.</td>
<td>Advaxis, Inc.</td>
<td>BrachyThermix, LLC</td>
</tr>
<tr>
<td>3:00 p.m. – 3:10 p.m.</td>
<td>Quoin Pharmaceuticals</td>
<td>ReGeITec, Inc.</td>
</tr>
<tr>
<td>3:10 p.m. – 3:20 p.m.</td>
<td>Matinas BioPharma Holdings, Inc.</td>
<td>OcuMedic, Inc.</td>
</tr>
</tbody>
</table>
3D Biotek, LLC (Gatsby, 10:30 a.m.-10:40 a.m.)
Founded in 2007 and headquartered in New Jersey, 3D Biotek is a biotechnology company engaged in developing 3-dimensional cell culture scaffolds by using its patented Precision 3D Micro-Fabrication Technology. 3D Insert is a series of novel 3D porous scaffolds for use in drug screening, stem cell research, and tissue engineering. The recently released product, 3D Cell Expansion System, enables large-scale stem cell expansion (500M) for bio-banking, stem cell based clinical trial and protein production for cosmetic industry. The next scale-up version for an expansion capacity of 5 billion cells is under development primarily for future stem cell therapy.

Presented by:
Wing K. Lau
Chief Executive Officer
wlau@3dbiotek.com
908-801-6138, ext. 101

Advaxis, Inc. (Gatsby, 2:50 p.m.-3:00 p.m.)
Advaxis, Inc. is a late-stage biotechnology company focused on the discovery, development and commercialization of proprietary Listeria monocytogenes [Lm] antigen delivery products based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins. These Lm-based strains are believed to be a significant advancement in immunotherapy as they integrate multiple functions into a single immunotherapy and are designed to access and direct antigen presenting cells to stimulate anti-tumor T cell immunity, activate immune systems with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment to enable T cells to eliminate tumors.

Presented by:
Kenneth Berlin
President & Chief Executive Officer
berlin@advaxis.com
609-250-7525

Amicus Therapeutics, Inc. (Gatsby, 2:30 p.m.-2:40 p.m.)
Amicus Therapeutics, Inc. (Nasdaq:FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering high-quality medicines for people living with rare metabolic diseases. With one rare disease medicine globally commercialized for Fabry disease, an investigational enzyme replacement therapy (AT-GAA) in late-stage development for the treatment of Pompe disease, and a robust gene therapy pipeline and growth platform for lysosomal storage disorders, Amicus Therapeutics, Inc. is committed to changing the lives of people with these life-threatening conditions.

Presented by:
Sara Pellegrino
Associate Director, Investor Relations
spellegrino@amicusrx.com
(609) 662-5044
ARKAY Therapeutics, LLC (Lecture Suite, 2:30 p.m.-2:40 p.m.)
ARKAY is a privately-held clinical stage company in East Windsor, NJ. We are raising capital for the clinical trials with our proprietary drug, TriGlytzaÔ, a first-in class, orally-active product for Type 2 diabetes (T2D). Unlike the currently marketed drugs which primarily treat the symptoms, TriGlytzaÔ treats the pathophysiology of progressive deterioration of beta cell function, the core defect in T2D patients. It is custom-formulated to prevent the clinical inertia and failure that occurs in ~50% of patients treated with current treatment options. TriGlytzaÔ fills clinically the most important gap: sustained glycemic control by preventing beta cell failure and insulin resistance.

Presented by:
Ravi Kumar, Ph.D.
Founder & Chief Executive Officer
Ravi.kumar@arkaytherapeutics.com
609-977-1857

BrachyThermix, LLC (Lecture Suite, 2:50 p.m.-3:00 p.m.)
BrachyThermix is developing a novel device to provide simultaneous and uniform heat and radiation to treat the tumor bed following surgical resection of a tumor. Our initial target is glioblastoma, an aggressive and deadly brain tumor. In a randomized clinical trial in human glioblastoma, non-uniform heating of tumor followed by non-uniform radiation doubled the 2-year survival rate. Animal studies have shown that simultaneous application of heat and radiation maximizes synergy between therapies.

Presented by:
Richard S. Woodward, Ph.D.
Co-Founder & Chief Executive Officer
Dick.woodward@brachythermix.com
856-753-7650

BrainTemp, Inc. (Lecture Suite, 10:30 a.m.-10:40 a.m.)
Brain Temp has developed the first passive continuous non-invasive system targeting the direct measurement of brain temperature. Non-Invasive Brain Temperature will become a new vital sign, critical to the diagnosis and treatment guidance in all disease states that require Targeted Temperature Management, including HIE, traumatic brain injury, stroke and sepsis.

Presented by:
Bryan Grulke
Partner, Volcano Capital
bgrulke@volcanocap.com
757-372-1762
Chromocell Corporation (Lecture Suite, 2:40 p.m.-2:50 p.m.)
Chromocell is a life sciences company which improves consumer products and patient lives through breakthrough science and technologies. Chromocell is focused on the discovery and development of therapeutics and flavors through the use of pioneering Chromovert® technology. Chromovert technology enables Chromocell to use rare cells ideally suited for effective high-throughput screening.

Presented by:
Kenneth Kashkin
Chief Operating Officer
Kenneth.kashkin@chromocell.com
732-565-1113

ConSynance Therapeutics (Gatsby, 11:40 a.m.-11:50 a.m.)
ConSynance is a clinical-stage, biopharma company focused on rare central nervous system diseases. ConSynance’s lead candidate, CSTI-100, is a first-in-class therapy for Prader-Willi Syndrome, a rare genetic neurodevelopmental disorder characterized by a false state of starvation, life-threatening hyperphagia, dysregulated neuro-endocrine signaling, anxiety, sleep disturbances, intellectual disability and morbid obesity. In a Phase 1 study of healthy overweight volunteers, CSTI-100 shows safety, bioavailability and significant reduction in appetite. ConSynance is led by an experienced management team that invented and developed CSTI-100 at Albany Molecular Research, Inc., (“AMRI”) and in-licensed CSTI-100 and other assets upon AMRI’s decision to exit proprietary drug development.

Presented by:
Peter Guzzo
Co-Founder & Chief Executive Officer
pete@consynance.com
518-275-0176

ContraFect Corporation (Gatsby, 2:00 p.m.-2:10 p.m.)
ContraFect is a biotechnology company focused on discovering and developing differentiated biologic therapeutics for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. We intend to address these infections using our therapeutic product candidates from our lysin platform and through the use of other novel agents. Our lead lysin candidate, exebacase (CF-301) is completing a Phase 2 clinical trial for the treatment of Staph aureus bacteremia, including endocarditis and is the first lysin to enter clinical studies in the U.S.

Presented by:
Roger Pomerantz
Chief Executive Officer
rpomerantz@contrafect.com
914-207-2300
Covalent Bioscience, Inc. (Lecture Suite, 11:30 a.m.-11:40 a.m.)
Covalent Bioscience owns two broadly enabling platform technologies for producing Catalytic Antibodies (Catabodies) and Electrophilic Vaccines (E-Vaccines) that address multi-billion-dollar markets – the platforms and our lead products have unique capabilities to fulfill major medical needs that are not met by conventional monoclonal antibodies and vaccines. Covalent has developed Cardizyme for treating amyloid-related diseases, including cardiomyopathy and musculoskeletal disease, and has the potential for undoing aging; Alzyme and Tauzyme for treating Alzheimer’s disease, and an HIV E-vaccine for world-wide prevention and functional cure of HIV infection.

Presented by:
Richard Massey
Chief Executive Officer
richardmassey@covalentbioscience.com
212-352-100

dB Diagnostic Systems, Inc. (Lecture Suite, 10:50 a.m.-11:00 a.m.)
dB Diagnostic Systems is a medical devices company looking to overcome the barriers that exist in the $8 billion hearing testing market with an easy-to-use hardware and software-powered solution that can provide accurate evaluations in just minutes. Fully developed with 510(k) FDA clearance, our Hearing Healthcare Pro™ Product Suite is being used in an active pilot with Ochsner Clinic (which provides over 50% of Louisiana’s healthcare), Montefiore Health, and New Jersey’s own Summit Medical Group. We’ve also secured our first patent, have two more pending, and operate two active manufacturing facilities in Florida and Connecticut.

Presented by:
Steven B. Levine, M.D.
President & Chief Executive Officer
slevine@dbdsys.com
203-404-3200, ext. 3

Elemental Machines (Lecture Suite, 11:00 a.m.-11:10 a.m.)
Elemental Machines develops sensors and an online informatics platform using the latest technologies, such as Internet of Things (IoT), Machines Learning and Artificial Intelligence (ML/AI) and Data Science. Our solutions automate real-time data collection from the physical world, comprising of various instrument data and ambient data. To make sense of this big data, we employ smart analytics tools for troubleshooting, predictive analytics and process optimization. The Elemental Machines connected platform is used to accelerate R&D and improve manufacturing yields, resulting in operational efficiencies and notable cost savings.

Presented by:
Sridhar Iyengar
Chief Executive Officer
sridhar@elementalmachines.io
617-319-2381
Goldilocks Therapeutics, Inc. (Lecture Suite, 11:20 a.m.-11:30 a.m.)
Goldilocks Therapeutics, Inc., was formed in 2018 to develop preventatives and/or treatments for renal disorders, such as acute kidney injury (AKI) and autosomal dominant polycystic kidney disease, two conditions that lack effective, indication-specific therapeutics. Our proprietary drug delivery technology utilizes “mesoscale” nanoparticles (MNPs) to specifically target the renal tubule epithelium and deliver therapeutic payloads in a sustained-release manner. The team has demonstrated proof-of-principle efficacy/safety in a clinically relevant murine AKI model using an MNP-based formulation of an FDA-approved small-molecule anti-oxidant. With an exclusive worldwide option on the MNP technology from Sloan Kettering, we are currently seeking Series A financing.

Presented by:
Arthur Klausner
President & Chief Executive Officer
ArthurK@GoldilocksTherapeutics.com
914-205-3862

Grace Therapeutics, Inc. (Gatsby, 11:20 a.m.-11:30 a.m.)
Rare and orphan disease company leveraging novel formulation and delivery technologies. $2 billion plus market potential for three leading product candidates, which address critical unmet needs in debilitating CNS conditions. All three are Phase 2 or 3 ready and carry orphan drug designation; with two additional pipeline products advancing to the clinic. Proven, experienced team with track record of commercial success.

Presented by:
Bruce Hochstadt, M.D., MBA
Chief Operating Officer
bhochstadt@gtrx.com
646-668-4507

Helsinn Therapeutics (U.S.), Inc (Lecture Suite, 2:00 p.m.-2:10 p.m.)
The Helsinn Group is a private, family-run pharmaceutical company, retaining our founding values of quality, integrity and respect, which guide everything we do. Our vision is to help people with cancer get the most out of every day. As one of the world’s leading cancer care companies, with a comprehensive portfolio of medicines and therapies helping to improve the lives of patients in 190 countries worldwide, we are committed to making everything we do – from the products we choose to license to the exacting standards we apply to manufacturing – count towards improving the lives of people with cancer.

Presented by:
Paul Rittman
Chief Executive Officer
Paul.rittman@helsinn.com
732-603-2856
iHealthScreen, Inc. (Lecture Suite, 10:40 a.m.-10:50 a.m.)
iHealthScreen, Inc. was established in 2015 with a focus on early screening and prediction of retinal and cardiovascular diseases to prevent blindness, death and disability. The company founder, Dr. Alauddin Bhuiyan has 13+ years of experience in this area. iHealthScreen won ~$850K of NIH SBIR grants and had already developed the HIPAA compliant telemedicine platform iPredict™ and electronic health record system based on which age-related macular degeneration, diabetic retinopathy, glaucoma, stroke and heart disease will be screened and prevented.

Presented by:
Alauddin Bhuiyan, Ph.D.
Founder & Chief Executive Officer
bhuiyan@ihealthscreen.org
718-926-9000

Intrommune Therapeutics (Gatsby, 10:50 a.m.-11:00 a.m.)
Intrommune Therapeutics, dedicated to improving and protecting the lives of people with food allergy, is developing the revolutionary oral mucosal immunotherapy (OMIT) treatment platform for food allergies. OMIT is a long-term, patient-friendly, disease-modifying solution for the 220 million people, including 9 million adults and 6 million children in the U.S., who suffer from life-altering food allergies. Intrommune’s lead product, INT301, is expected to be a safe, effective and convenient therapy for patients who suffer from peanut allergy, will be applied as a patient brushes their teeth. There is no FDA approved treatment for peanut allergy or any other food allergy.

Presented by:
Michael Nelson, J.D.
Chief Executive Officer
mnelson@intrommune.com
646-494-8432

Kaydence Pharma A.S. (Gatsby, 11:30 a.m.-11:40 a.m.)
Kaydence Pharma is an emerging pharmaceutical company focused on the development of menaquinone-7 (MQ-7), a drug candidate for the treatment of vascular calcification. KP is pursuing this novel therapy for patients with chronic kidney disease, a group for whom vascular calcification and the associated loss of arterial flexibility is the leading cause of morbidity and mortality. Capitalizing on over 10 years of research and compelling proof-of-concept work, KP holds patents for clinical applications of menaquinones and for its proprietary process technology. The company is privately owned, with operations in both New Brunswick, NJ and Oslo, Norway.

Presented by:
Daniel H. Rosenbaum
Chief Executive Officer
Daniel.rosenbaum@kaydencepharma.com
215-327-5628
Matinas BioPharma Holdings, Inc. (Gatsby, 3:10 p.m.-3:20 p.m.)
Matinas BioPharma is a clinical-stage biopharmaceutical company developing the application of its lipid nano-crystal (“LNC”) platform technology to solve complex challenges relating to the safe and effective delivery of small molecules, gene therapies, proteins, peptides and vaccines. The LNC platform delivers therapeutic drug candidates intracellularly in a non-destructive manner, leveraging naturally activated target cells including those of the immune system or virally infected cells. Matinas is utilizing its LNC technology for MAT2203, an orally-administered, LNC formulation of amphotericin B.

Presented by:
Theresa Matkovits, Ph.D.
Chief Development Officer
tmatkovits@matinasbiopharma.com
(908) 505-0975

Micro Interventional Devices, Inc. (Gatsby, 10:40 a.m.-10:50 a.m.)
Micro Interventional Devices, Inc. (MID), is an emerging medical device company that designs, manufactures and commercializes disruptive technologies enabling percutaneous and minimally invasive structural heart repair procedures. The technology platform includes Permaseal™, a minimally invasive transapical access and closure device, MIA™, a transcatheter mitral and tricuspid valve repair device, and PermaValve™, a transcatheter mitral valve replacement device. These technologies utilize the same proprietary components to replicate open surgical procedures on the end of catheter-based high-speed delivery systems, enabling less-invasive cardiovascular procedures and expanding the patient population eligible for treatment.

Presented by:
Katherine Whitman
Director of Marketing
kwhitman@microinterventional.com
215-208-6942

Mito BioPharma (Gatsby, 11:10 a.m.-11:20 a.m.)
Founded in 2012, Mito BioPharma has developed a transformative small-molecule mitochondrial modulating therapeutic technology and pipelines for treating metabolism-related diseases. The current therapeutic focuses are NASH and Type 2 Diabetes. Proof-of-concept study has been published in high impact journals (e.g. Nature Medicine). Our compound pipelines are protected by world-wide composition-of-matter patents, with one key patent already issued in the U.S., in March 2019. Currently, the therapeutic leads for NASH and T2D are available for further development. We are seeking investment and partnership to advance the development programs of NASH and Type 2 Diabetes.

Presented by:
Victor Jin, Ph.D.
Founder
Victor_jin@mitobiopharma.com
917-686-2636
Neuronasal, LLC (Gatsby, 11:00 a.m.-11:10 a.m.)
Neuronasal has a drug device combination using intellectual property invented jointly by Neuronasal and Weill Cornell Medical. The Cornell co-inventor, Professor Raj Ratan, has also discovered the mode of action (published recently in *Annals of Neurology*). We are developing a treatment for concussion, a major unmet need. Our drug device combination is based on a market-proven device and drug and is ready for human trials. Neuronasal has an experienced drug development team. This is the first of several indications. Nose to brain delivery is a promising route for many problematic brain treatments; Neuronasal is at the forefront of this area.

*Presented by:*
Thomas Bradshaw
Chief Executive Officer, Managing Member
tom@neuronasal.com
215-833-3080

OcuMedic, Inc. (Lecture Suite, 3:10 p.m.-3:20 p.m.)
OcuMedic's is developing proprietary timed drug delivery to the eye via a contact lens/clear corneal bandage to eliminate the need for eye drops. There are 10 issued patents, and a Freedom to Operate opinion. Efficacy has been proven in an animal model. The intellectual property teaches a novel therapeutic contact lens with memory capable of controlled release of “first line” ophthalmic agents; anti-inflammatory, antibiotic and steroids. The technology uses the most common contact lens material silicon hydrogel. The technology has been tested with (10) other drugs and molecules to enhance lens comfort and treat dry eye.

*Presented by:*
Keith Ignotz
President & Chief Executive Officer
kignotz@ocumedics.com
404-444-6030

OncoSec Medical, Inc. (Gatsby, 2:10 p.m.-2:20 p.m.)
OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies with new technologies to stimulate the body’s immune system to target and attack cancer. Their investigational platform, Intratumoral IL-12, is designed to enhance local delivery and uptake of DNA-based therapeutics directly into tumors. Clinical studies of Intratumoral IL-12 with plasmid encoded IL-12 (tavokinogene telseplasmid or “TAVO”) demonstrated a local immune response, and subsequently, a systemic effect as either a monotherapy or combination treatment approach. To date, study results have laid the groundwork for OncoSec's expansion into new DNA-encoded therapeutic candidates and tumor indications.

*Presented by:*
Daniel J. O’Connor, J.D.
President & Chief Executive Officer
djo@oncosec.com
609-363-9770
PolyAurum, LLC (Lecture Suite 11:40 a.m.-11:50 a.m.)
PolyAurum is a pre-clinical stage biotechnology start-up spun out of the University of Pennsylvania to
develop biodegradable gold nanoparticles (BGNP) for treating cancer. Of the 1.7 million Americans
diagnosed with cancer each year, roughly half of them receive radiotherapy. But for certain locally
advanced tumors, there is a high rate of therapy failure which leads to disease progression and death.
PolyAurum’s gold nanoparticles enter tumors selectively through a radiation enhanced penetration
and accumulation effect, and significantly amplify the effect of radiotherapy in the tumor only, without
increasing harm to healthy tissues adjacent to the tumor, i.e. increasing the therapeutic window.

Presented by:
Debra Travers
President & Chief Executive Officer
dstravers@polyaurum.com
484-802-2328

Quoin Pharmaceuticals (Gatsby, 3:00 p.m.-3:10 p.m.)
Quoin is a specialty pharma company with a differentiated polymer drug delivery platform technology.
Our scaled up and commercialized technology is ideal for transdermal and topical delivery as it provides
for a controlled rate of penetration across the skin resulting in an extended duration of efficacy. We have
four lead products under development addressing underserved and attractive market opportunities
in orphan dermatology to treat Netherton Syndrome and Dystrophic Epidermolysis Bullosa and CNS
targeting medical emergencies, such as the opioid epidemic and the military veteran suicide crisis that
combined account for more than 120 deaths in the U.S. every single day.

Presented by:
Denise Carter
Chief Operating Officer
dcarter@quoinpharma.com
610-662-4025

ReGelTec, Inc. (Lecture Suite, 3:00 p.m.-3:10 p.m.)
ReGelTec, Inc. is a medical device company developing the next generation of minimally invasive
spinal implants for lower back pain and degenerative disc disease. ReGelTec’s Hydrafil™ solution is a
percutaneous treatment for degenerative disc disease delivered via an 18-gauge needle to alleviate
lower back pain and restore physiological loading of the spine designed to allow patients to return to
normal physical activity. The company’s lead product is a proprietary hydrogel technology that can be
injected into the nucleus of an intervertebral disc as a liquid and solidifies between the vertebrae to
eliminate pain while maintaining structural stability.

Presented by:
Bill Niland
President & Chief Executive Officer
bniland@regeltc.com
443-956-4465
Sapience Therapeutics, Inc. (Lecture Suite, 2:20 p.m.-2:30 p.m.)
Sapience Therapeutics, Inc., is focused on discovering and developing peptide-based therapeutics to previously ‘undruggable’ targets for major unmet medical needs, particularly high mortality cancers. With platform-based discovery capabilities, Sapience generates novel peptides to disrupt protein-protein interactions with a focus on disruption of oncogenic transcription complexes, signaling pathways and immune-modulatory mechanisms. The lead program is directed toward the treatment of various solid tumors and hematologic malignancies, including breast cancer, glioblastoma and acute myeloid leukemia. Sapience is also developing a robust pipeline of additional molecules to disrupt well-known oncogenic signaling pathways.

Presented by:
Barry Kappel, Ph.D., MBA
President & Chief Executive Officer
barry@sapiencetherapeutics.com
914-607-6931

SCYNEXIS, Inc. (Gatsby, 2:20 p.m.-2:30 p.m.)
SCYNEXIS, Inc. (NASDAQ:SCYX) is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by developing innovative therapies. The SCYNEXIS team has extensive experience in the life sciences industry, having discovered and developed more than 30 innovative medicines over a broad range of therapeutic areas. SCYNEXIS’ lead product candidate, ibrexafungerp (formerly known as SCY-078), is a novel IV/oral antifungal agent in Phase 3 clinical and preclinical development for the treatment of multiple serious and life-threatening invasive fungal infections caused by Candida, Aspergillus and Pneumocystis species.

Presented by:
Marco Taglietti, M.D.
President & Chief Executive Officer
marco.taglietti@scynexis.com
646-395-3734

Shifa Biomedical Corporation (Lecture Suite, 11:10 a.m.-11:20 a.m.)
Shifa Biomedical Corporation is a privately held company dedicated to the development of drugs for the treatment of cardiovascular disease. Shifa has expertise in the discovery of small molecule, including pharmaceutical experience guided by biochemical, cell-based assays and virtual screening. Shifa’s experienced scientists exploit molecular biology, biochemistry, crystallography and medicinal, computational and combinatorial chemistry to discover and develop new medicines. Shifa is focused on development of P-21, a novel patented orally bioavailable small molecule that interferes with the function of PCSK9 and in animal studies has been shown to lower LDL-cholesterol to the same extent as currently approved monoclonal antibodies.

Presented by:
Sherin S. Abdel-Meguid, Ph.D.
President
Sherin.s.abdel-meguid@shifabiomedical.com
610-400-1243
SHINKEI Therapeutics, LLC (Lecture Suite, 2:10 p.m.-2:20 p.m.)  
SHINKEI is a private, clinical-stage, pharmaceutical product development company. Our mission is to develop products with a focus on improving a drug’s administration such that it allows use in indications not previously possible, enhances the convenience, improves compliance and/or ameliorates the side-effects profile for patients. The company’s initial efforts are directed towards drugs used to treat central nervous system (CNS) disorders.

Presented by:
GP Singh Sachdeva
Chairman
gpsingh@shinkeitherapeutics.com
734-968-7823

Tyme Technologies, Inc. (Gatsby, 2:40 p.m.-2:50 p.m.)  
Tyme Technologies, Inc., is an emerging biotechnology company developing cancer therapeutics that are intended to be broadly effective across tumor types and have low toxicity profiles. Unlike targeted therapies that attempt to regulate specific mutations within cancer, the company’s therapeutic approach is designed to take advantage of a cancer cell’s innate metabolic weaknesses to compromise its defenses, leading to cell death through oxidative stress and exposure to the body’s natural immune system. For more information, visit www.tymeinc.com. Follow us on social media: @tyme_Inc, LinkedIn, Instagram, Facebook and YouTube.

Presented by:
Michele Korfin
Chief Operating Officer
Michele.korfin@tymeinc.com
908-421-1591